Considerations for Drug Development in Myelodysplastic Syndromes

Overview of attention for article published in Clinical Cancer Research, January 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 25 X users

Readers on

mendeley: 8 Mendeley

So far, Altmetric has seen 33 X posts from 25 X users, with an upper bound of 122,695 followers.

RT @Ramikomrokji: Our new manuscript, kudos to @MikkaelSekeres leading this effort and grateful to the FDA vision to get this panel togethe…

RT @MikkaelSekeres: So happy to share this amazing collaboration with @US_FDA on Considerations for Drug Development in Myelodysplastic Syn…

RT @Ramikomrokji: Our new manuscript, kudos to @MikkaelSekeres leading this effort and grateful to the FDA vision to get this panel togethe…

RT @dstarczynowski: Considerations for drug development in #MDS ⁦@CCR_AACR⁩ https://t.co/yPvBIwnggN

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 29 additional X posts.